The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Resection of Retained Products of Conception

Launched by FU XING HOSPITAL, CAPITAL MEDICAL UNIVERSITY · Oct 9, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating whether a special gel called auto-cross linked hyaluronic acid can help prevent the formation of scar tissue inside the uterus after a surgical procedure to remove retained products of conception (RPOC). RPOC can occur after pregnancy and may affect a woman's future ability to conceive if not treated properly. In this study, women diagnosed with RPOC will be randomly divided into two groups: one group will receive the gel after surgery, while the other group will not. The researchers will then check the patients at two follow-up visits to see if the gel helps reduce the chance of scar tissue forming, which can lead to menstrual problems and difficulties in getting pregnant.

To participate in this trial, women aged between 18 and 45 who have been diagnosed with RPOC and can provide written consent may be eligible. However, women with serious health issues, infections in the genital area, or those who do not understand the study will not be included. Participants can expect to have a couple of follow-up appointments to monitor their recovery and menstrual patterns, as well as to track pregnancy outcomes for up to a year after the surgery. This study aims to find out if the gel can make a difference in women's reproductive health after dealing with RPOC.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of retained products of conception
• • Written consent obtained
• Exclusion Criteria:
• • Patients with severe complications of medicine and surgery
• • Acute or chronic genital tract inflammation
• • No understanding or approving the randomized controlled trial